The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.

MLA

Choy, Ernest H. S., et al. “The Effect of JAK1/JAK2 Inhibition in Rheumatoid Arthritis: Efficacy and Safety of Baricitinib.” Clinical and Experimental Rheumatology, vol. 37, no. 4, July 2019, pp. 694–704. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=30767864&authtype=sso&custid=ns315887.

APA

Choy, E. H. S., Miceli-Richard, C., González-Gay, M. A., Sinigaglia, L., Schlichting, D. E., Meszaros, G., de la Torre, I., & Schulze-Koops, H. (2019). The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib. Clinical and Experimental Rheumatology, 37(4), 694–704.

Chicago

Choy, Ernest H S, Corinne Miceli-Richard, Miguel A González-Gay, Luigi Sinigaglia, Douglas E Schlichting, Gabriella Meszaros, Inmaculada de la Torre, and Hendrik Schulze-Koops. 2019. “The Effect of JAK1/JAK2 Inhibition in Rheumatoid Arthritis: Efficacy and Safety of Baricitinib.” Clinical and Experimental Rheumatology 37 (4): 694–704. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=30767864&authtype=sso&custid=ns315887.